| Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ... Nature communications 11 (1), 1996, 2020 | 224 | 2020 |
| DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ... Journal of hematology & oncology 13, 1-13, 2020 | 101 | 2020 |
| Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity Y He, W Li, D Lv, X Zhang, X Zhang, YT Ortiz, V Budamagunta, J Campisi, ... Aging cell 19 (3), e13117, 2020 | 91 | 2020 |
| Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ... European journal of medicinal chemistry 199, 112397, 2020 | 54 | 2020 |
| Cellular senescence in lymphoid organs and immunosenescence V Budamagunta, TC Foster, D Zhou Aging (Albany NY) 13 (15), 19920, 2021 | 51 | 2021 |
| Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 D Thummuri, S Khan, PW Underwood, P Zhang, J Wiegand, X Zhang, ... Molecular cancer therapeutics 21 (1), 184-192, 2022 | 45 | 2022 |
| Senescence-associated hyper-activation to inflammatory stimuli in vitro V Budamagunta, S Manohar-Sindhu, Y Yang, Y He, DO Traktuev, ... Aging (Albany NY) 13 (15), 19088, 2021 | 41 | 2021 |
| BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Journal of Hematology & Oncology 15 (1), 23, 2022 | 39 | 2022 |
| Nanovesicle and extracellular polymeric substance synthesis from the remediation of heavy metal ions from soil V Budamagunta, N Shameem, S Irusappan, JA Parray, M Thomas, ... Environmental Research 219, 114997, 2023 | 31 | 2023 |
| Effect of peripheral cellular senescence on brain aging and cognitive decline V Budamagunta, A Kumar, A Rani, L Bean, S Manohar‐Sindhu, Y Yang, ... Aging Cell 22 (5), e13817, 2023 | 28 | 2023 |
| Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice S Khan, P Kellish, N Connis, D Thummuri, J Wiegand, P Zhang, X Zhang, ... Cell Death Discovery 9 (1), 1, 2023 | 24 | 2023 |
| Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies S Khan, V Budamagunta, D Zhou Advances in Cancer Research 159, 145-184, 2023 | 12 | 2023 |
| DT2216, a BCL-XL proteolysis targeting chimera (PROTAC), is a potent anti T-cell lymphoma agent that does not induce significant thrombocytopenia Y He, R Koch, V Budamagunta, D Lv, S Khan, X Zhang, JS Wiegand, ... Blood 134, 303, 2019 | 5 | 2019 |
| Senolytic treatment alleviates doxorubicin‐induced chemobrain V Budamagunta, A Kumar, A Rani, S Manohar Sindhu, Y Yang, D Zhou, ... Aging cell 23 (2), e14037, 2024 | 4 | 2024 |
| Failure of senolytic treatment to prevent cognitive decline in a female rodent model of aging A Rani, L Bean, V Budamagunta, A Kumar, TC Foster Frontiers in Aging Neuroscience 16, 1384554, 2024 | 3 | 2024 |
| A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Cancer Research 82 (12_Supplement), 5313-5313, 2022 | 2 | 2022 |
| The Uncharted Avenues of Cellular Senescence V Budamagunta University of Florida, 2022 | | 2022 |
Daohong ZhouUniversity of Texas Health Science Center at San AntonioVerified email at uthscsa.edu